(Q37811110)

23 August 2017

Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis (English)

1 reference

23 August 2017

0 references

African trypanosomiasis

0 references

visceral leishmaniasis

1 reference

1

M Boelaert

1 reference

23 August 2017

F Meheus

2

1 reference

PubMed ID

21092391

23 August 2017

J Robays

series ordinal

3

1 reference

PubMed ID

21092391

23 August 2017

P Lutumba

series ordinal

4

1 reference

23 August 2017

1 October 2010

1 reference

Annals of Tropical Medicine and Parasitology

23 August 2017

1 reference

23 August 2017

104

1 reference

23 August 2017

7

1 reference

23 August 2017

535-542

1 reference

Paying for hospital-based care of Kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences

23 August 2017

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Leishmaniasis and poverty

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Human African trypanosomiasis in areas without surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Leishmaniasis. Public health aspects and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Spread of vector-borne diseases and neglect of Leishmaniasis, Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Management of visceral leishmaniasis in rural primary health care services in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Human African trypanosomiasis in a rural community, Democratic Republic of Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The economic burden of visceral leishmaniasis for households in Nepal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Epidemiology of Leishmania donovani infection in high-transmission foci in Nepal

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

A prospective sero-epidemiological study of visceral leishmaniasis in Baringo district, Rift Valley Province, Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The economic impact of visceral leishmaniasis on households in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The epidemiology of Leishmania donovani infection in high transmission foci in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

The situation of sleeping sickness in Angola: a calamity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Household cost-of-illness of visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Drugs for neglected diseases: a failure of the market and a public health failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12786389891641

10.1179/136485910X12786389891641

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21092391